DALY and HLY in Portugal, 1990–2019. The first graph shows a decreasing trend of DALY and the second graph shows an increasing trend of HLY. by Aida Isabel Tavares (12080156)

Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia. by Francesca Catto (21253435)

“…However, when high doses of netoglitazone are administered for long-term, it produces a significant and scattered effect, leading to a noticeable reduction in microglia volume in cortical and hippocampal regions. …”

<b>Manure improves temperature sensitivity of soil organic carbon by increasing soil alphaproteobacteria, phenols, and pH and decreasing soil esters</b> by Andong Cai (5237024)

“…</a>However, the relative importance of soil organic compounds in the regulation of the Q₁₀ remains unclear, which is attributed to the relative stability of soil organic compounds. Long-term different fertilization could change the quantity and quality of soil organic compounds. …”

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

“…(D) Long-term treatment with a high dose of netoglitazone demonstrates a considerable decrease in plaque count, especially in the olfactory, striatum, pallidum, hindbrain, and midbrain regions.…”

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

“…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”

SWFT scores and Lactate Levels. by Burhan Demirkıran (21601740)

Subjects:

The weekly content of the 8-week training program. by Burhan Demirkıran (21601740)

Subjects:

HRV Values. by Burhan Demirkıran (21601740)

Subjects:

Changes in subcutaneous fat thickness and muscle mass (Approximately here). by Burhan Demirkıran (21601740)

Subjects:

HRV values (Approximately here). by Burhan Demirkıran (21601740)

Subjects:

Trial Design (Approximately Here). by Burhan Demirkıran (21601740)

Subjects:

Supplementary Figure. by Burhan Demirkıran (21601740)

Subjects:

Biweekly Changes in Body Weight, Body Fat Percentage, Muscle Mass, and BMI During the Retraining Period. by Burhan Demirkıran (21601740)

Subjects:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”